A1 adenosine receptor knockout mice exhibit increased mortality, renal dysfunction, and hepatic injury in murine septic peritonitis

被引:68
作者
Gallos, G [1 ]
Ruyle, TD [1 ]
Emala, CW [1 ]
Lee, HT [1 ]
机构
[1] Columbia Univ, Coll Phys & Surg, Dept Anesthesiol, Anesthesiol Res Labs, New York, NY 10032 USA
关键词
acute renal failure; multiorgan injury; survival;
D O I
10.1152/ajprenal.00470.2004
中图分类号
Q4 [生理学];
学科分类号
071003 ;
摘要
Sepsis is a leading cause of multiorgan dysfunction and death in hospitalized patients. Dysregulated inflammatory processes and apoptosis contribute to the pathogenesis of sepsis-induced organ dysfunction and death. A(1) adenosine receptor (A(1)AR) activation reduces inflammation and apoptosis after ischemia-reperfusion injury. Therefore, we questioned whether A(1)AR-mediated reduction of inflammation and apoptosis could improve mortality and organ dysfunction in a murine model of sepsis. A(1)AR knockout mice (A(1) knockout) and their wild-type (A(1) wild-type) littermate controls were subjected to cecal ligation and double puncture (CLP) with a 20-gauge needle. A(1) knockout mice or A(1) wild-type mice treated with 1,3-dipropyl-8-cyclopentylxanthine (a selective A(1)AR antagonist) had a significantly higher mortality rate compared with A(1) wild-type mice following CLP. Mice lacking endogenous A(1)ARs demonstrated significant elevations in plasma creatinine, alanine aminotransferase, aspartate aminotransferase, keratinocyte-derived chemokine, and tumor necrosis factor-alpha 24 h after induction of sepsis compared with wild-type mice. The renal corticomedullary junction from A(1) knockout mice also exhibited increased myeloperoxidase activity, intercellular adhesion molecule-1 protein, and mRNA encoding proinflammatory cytokines compared with renal samples from A(1) wild-type littermate controls. No difference in renal tubular apoptosis was detected between A(1) knockout and A(1) wild-type mice. We conclude that endogenous A(1)AR activation confers a protective effect in mice from septic peritonitis primarily by attenuating the hyperacute inflammatory response in sepsis.
引用
收藏
页码:F369 / F376
页数:8
相关论文
共 42 条
[1]   Inhibiting adenosine deaminase modulates the systemic inflammatory response syndrome in endotoxemia and sepsis [J].
Adanin, S ;
Yalovetskiy, IV ;
Nardulli, BA ;
Sam, AD ;
Jonjev, IS ;
Law, WR .
AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY, 2002, 282 (05) :R1324-R1332
[2]   Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome, and associated costs of care [J].
Angus, DC ;
Linde-Zwirble, WT ;
Lidicker, J ;
Clermont, G ;
Carcillo, J ;
Pinsky, MR .
CRITICAL CARE MEDICINE, 2001, 29 (07) :1303-1310
[3]   Predictive value of nuclear factor κB activity and plasma cytokine levels in patients with sepsis [J].
Arnalich, F ;
Garcia-Palomero, E ;
López, J ;
Jiménez, M ;
Madero, R ;
Renart, J ;
Vazquez, JJ ;
Montiel, C .
INFECTION AND IMMUNITY, 2000, 68 (04) :1942-1945
[4]   Mechanisms of disease - Nuclear factor-kappa b - A pivotal transcription factor in chronic inflammatory diseases [J].
Barnes, PJ ;
Larin, M .
NEW ENGLAND JOURNAL OF MEDICINE, 1997, 336 (15) :1066-1071
[5]   MOF/MODS, SIRS: An update [J].
Baue, AE .
SHOCK, 1996, 6 :S1-S5
[6]   MULTIPLE ORGAN FAILURE SYNDROME IN THE 1990S - SYSTEMIC INFLAMMATORY RESPONSE AND ORGAN DYSFUNCTION [J].
BEAL, AL ;
CERRA, FB .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1994, 271 (03) :226-233
[7]   Sepsis: A new hypothesis for pathogenesis of the disease process [J].
Bone, RC ;
Grodzin, CJ ;
Balk, RA .
CHEST, 1997, 112 (01) :235-243
[8]   DEFINITIONS FOR SEPSIS AND ORGAN FAILURE AND GUIDELINES FOR THE USE OF INNOVATIVE THERAPIES IN SEPSIS [J].
BONE, RC ;
BALK, RA ;
CERRA, FB ;
DELLINGER, RP ;
FEIN, AM ;
KNAUS, WA ;
SCHEIN, RMH ;
SIBBALD, WJ .
CHEST, 1992, 101 (06) :1644-1655
[9]   Hypoxia-induced inhibition of adenosine kinase potentiates cardiac adenosine release [J].
Decking, UKM ;
Schlieper, G ;
Kroll, K ;
Schrader, J .
CIRCULATION RESEARCH, 1997, 81 (02) :154-164
[10]  
Ebong S, 1999, INFECT IMMUN, V67, P6603